\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ physical\\ exam\\.\\ urinalysis\\ was\\ consistent\\ with\\ gross\\ hematuria\\,\\ no\\ crystals\\ were\\ visualized\\,\\ wbc\\'s\\ were\\ within\\ normal\\ limits\\.\ \(0\)\
\-\ transurethral\\ resection\\ of\\ bladder\\ tumor\\,\\ turbt\\,\\ with\\ biopsy\\ of\\ remaining\\ bladder\\ and\\ prostatic\\ urethra\\ is\\ normally\\ sufficient\\ for\\ low\\-grade\\ urothelial\\ cancer\\.\\ adjuvant\\ intravesicular\\ therapy\\ may\\ be\\ included\\ for\\ cases\\ of\\ high\\-grade\\ urothelial\\ cancer\\.\\ bcg\\ is\\ most\\ commonly\\ used\\ due\\ to\\ its\\ favorable\\ toxicity\\ profile\\ and\\ its\\ efficacy\\.\\ six\\ months\\ of\\ bcg\\ therapy\\ is\\ usually\\ required\\ to\\ qualify\\ as\\ bcg\\ resistant\\ tumors\\.\\ alternatives\\ for\\ these\\ tumors\\ include\\ adding\\ mitomycin\\ c\\,\\ anthracyclines\\,\\ and\\ interferon\\.\ \(0\)\
\-\ high\\ grade\\ tumors\\ are\\ most\\ likely\\ to\\ be\\ muscle\\-invasive\\.\\ mvac\\ is\\ considered\\ first\\ line\\ multi\\-agent\\ chemotherapy\\.\ \(0\)\
\-\ follow\\-up\\ includes\\ screening\\ cystography\\ for\\ recurrence\\ of\\ disease\\ which\\ is\\ not\\ uncommon\\.\ \(0\)\
\-\ bilateral\\ extrarenal\\ pelves\\.\ \(0\)\
\-\ no\\ evidence\\ of\\ obstructing\\ stones\\ or\\ stones\\ in\\ the\\ bladder\\.\\ \\ \ \(0\)\
\-\ abnormal\\ layering\\ of\\ contrast\\ material\\ within\\ the\\ posterior\\ aspect\\ of\\ the\\ bladder\\ concerning\\ for\\ clot\\ vs\\ mural\\ mass\\.\ \(0\)\
\-\ metastatic\\ disease\\ with\\ spread\\ to\\ bilateral\\ hilar\\ and\\ mediastinal\\ lymph\\ nodes\\.\ \(0\)\
\-\ metastatic\\ disease\\ with\\ spread\\ to\\ left\\ lower\\ lung\\ lobe\\.\ \(0\)\
\-\ urothelial\\ cancer\ \(3\)\
\-\ bladder\\ cancer\\ \\-\\ mainly\\ urothelial\\ \\(transitional\\ cell\\)\\ cancer\ \(0\)\
\-\ bph\ \(3\)\
\-\ renal\\ stones\ \(7\)\
\-\ cystitis\ \(180\)\
\-\ 82\\ yo\\ man\\ with\\ 2\\-month\\ history\\ of\\ painless\\ gross\\ hematuria\ \(1\)\
\-\ this\\ man\\ had\\ metastasis\\ to\\ his\\ right\\ acetabulum\\ and\\ right\\ femur\\,\\ right\\ lower\\ lung\\,\\ and\\ caudate\\ lobe\\ of\\ the\\ liver\\,\\ with\\ large\\ infiltration\\ of\\ mediastinal\\ and\\ perihilar\\ lymph\\ nodes\\.\\ up\\ to\\ 45\\%\\ of\\ new\\ urothelial\\ cancers\\ are\\ high\\ grade\\ and\\ half\\ of\\ those\\ are\\ already\\ invasive\\.\\ metastases\\ most\\ commonly\\ travel\\ to\\ lung\\ and\\ liver\\.\ \(0\)\
\-\ this\\ patient\\'s\\ initial\\ non\\-contrast\\ ct\\ \\ did\\ not\\ clearly\\ show\\ the\\ mural\\ mass\\ as\\ it\\ is\\ shown\\ here\\.\\ his\\ enlarged\\ prostate\\ produced\\ a\\ mass\\ effect\\ indenting\\ the\\ contour\\ of\\ the\\ posterior\\ bladder\\ wall\\.\\ this\\ highlights\\ the\\ need\\ for\\ careful\\ evaluation\\ of\\ the\\ bladder\\ wall\\ when\\ it\\ is\\ opposed\\ by\\ the\\ prostate\\ and\\ having\\ a\\ properly\\ distended\\ bladder\\ to\\ evaluate\\ thickening\\ of\\ the\\ trabeculated\\ bladder\\ wall\\.\ \(0\)\
\-\ this\\ patient\\'s\\ hilar\\ and\\ mediastinal\\ lymphadenopathy\\ with\\ mass\\ effect\\ on\\ the\\ pulmonary\\ vessels\\ aggravated\\ this\\ man\\'s\\ congestive\\ heart\\ failure\\ with\\ frequent\\ admissions\\ for\\ exacerbations\\ to\\ rule\\ out\\ pulmonary\\ embolisms\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ bladder\\:\\ 0\\.35324924878442143\ \(0\)\
\-\ urothelial\\:\\ 0\\.3288610184751559\ \(0\)\
\-\ bcg\\:\\ 0\\.21828999011658023\ \(0\)\
\-\ cancer\\:\\ 0\\.1684482474871864\ \(0\)\
\-\ of\\:\\ 0\\.15837154148433177\ \(0\)\
\-\ grade\\:\\ 0\\.14548479309361237\ \(0\)\
\-\ stones\\:\\ 0\\.14323983299869153\ \(0\)\
\-\ to\\:\\ 0\\.12644823000819586\ \(0\)\
\-\ mediastinal\\:\\ 0\\.12252682006662878\ \(0\)\
\-\ the\\:\\ 0\\.1211097693268673\ \(0\)\
\-\ and\\:\\ 0\\.11496840930731603\ \(0\)\
\-\ tumors\\:\\ 0\\.11159627333576241\ \(0\)\
\-\ for\\:\\ 0\\.1073122097580042\ \(0\)\
\-\ mural\\:\\ 0\\.10332854385495344\ \(0\)\
\-\ prostate\\:\\ 0\\.09798227485159353\ \(0\)\
\-\ is\\:\\ 0\\.09696114110148395\ \(0\)\
\-\ hilar\\:\\ 0\\.09275956274794996\ \(0\)\
\-\ lung\\:\\ 0\\.09230462905580682\ \(0\)\
\-\ wall\\:\\ 0\\.09230462905580682\ \(0\)\
\-\ invasive\\:\\ 0\\.09205012083575242\ \(0\)\
\-\ spread\\:\\ 0\\.09087304642082257\ \(0\)\
\-\ gross\\:\\ 0\\.08976926106179887\ \(0\)\
\-\ hematuria\\:\\ 0\\.08946611380387788\ \(0\)\
\-\ this\\:\\ 0\\.08690046074842092\ \(0\)\
\-\ high\\:\\ 0\\.08623854429051189\ \(0\)\
\-\ nodes\\:\\ 0\\.08593482905378703\ \(0\)\
\-\ turbt\\:\\ 0\\.08088793461005986\ \(0\)\
\-\ anthracyclines\\:\\ 0\\.08088793461005986\ \(0\)\
\-\ mvac\\:\\ 0\\.08088793461005986\ \(0\)\
\-\ man\\:\\ 0\\.08033254674412145\ \(0\)\
\-\ with\\:\\ 0\\.0792330842213154\ \(0\)\
\-\ most\\:\\ 0\\.07896960599626923\ \(0\)\
\-\ lymph\\:\\ 0\\.07866252854147895\ \(0\)\
\-\ pelves\\:\\ 0\\.07729273981412468\ \(0\)\
\-\ embolisms\\:\\ 0\\.07729273981412468\ \(0\)\
\-\ mass\\:\\ 0\\.07728036448566022\ \(0\)\
\-\ commonly\\:\\ 0\\.07485308475385846\ \(0\)\
\-\ its\\:\\ 0\\.07485308475385846\ \(0\)\
\-\ intravesicular\\:\\ 0\\.07474190851180067\ \(0\)\
\-\ qualify\\:\\ 0\\.07474190851180067\ \(0\)\
\-\ admissions\\:\\ 0\\.07474190851180067\ \(0\)\
\-\ alternatives\\:\\ 0\\.07276333003886008\ \(0\)\
\-\ mitomycin\\:\\ 0\\.07276333003886008\ \(0\)\
\-\ bph\\:\\ 0\\.07114671371586548\ \(0\)\
\-\ effect\\:\\ 0\\.07096197511987723\ \(0\)\
\-\ liver\\:\\ 0\\.06978441505685964\ \(0\)\
\-\ adding\\:\\ 0\\.06977988409027662\ \(0\)\
\-\ cystography\\:\\ 0\\.06977988409027662\ \(0\)\
\-\ transurethral\\:\\ 0\\.06859588241354148\ \(0\)\
\-\ extrarenal\\:\\ 0\\.06859588241354148\ \(0\)\
\-\ trabeculated\\:\\ 0\\.06859588241354148\ \(0\)\
\-\ interferon\\:\\ 0\\.06755151891993029\ \(0\)\
\-\ indenting\\:\\ 0\\.06577220369503119\ \(0\)\
\-\ highlights\\:\\ 0\\.06577220369503119\ \(0\)\
\-\ exacerbations\\:\\ 0\\.06577220369503119\ \(0\)\
\-\ disease\\:\\ 0\\.06369467028122056\ \(0\)\
\-\ crystals\\:\\ 0\\.0630221091446657\ \(0\)\
\-\ aggravated\\:\\ 0\\.0630221091446657\ \(0\)\
\-\ prostatic\\:\\ 0\\.062449856315282284\ \(0\)\
\-\ pulmonary\\:\\ 0\\.06166130497642648\ \(0\)\
\-\ toxicity\\:\\ 0\\.0614054928216711\ \(0\)\
\-\ efficacy\\:\\ 0\\.0614054928216711\ \(0\)\
\-\ his\\:\\ 0\\.06135072466075025\ \(0\)\
\-\ properly\\:\\ 0\\.060926087347181496\ \(0\)\
\-\ cystitis\\:\\ 0\\.05962617759677199\ \(0\)\
\-\ perihilar\\:\\ 0\\.05962617759677199\ \(0\)\
\-\ travel\\:\\ 0\\.05962617759677199\ \(0\)\
\-\ caudate\\:\\ 0\\.05923203086930025\ \(0\)\
\-\ adjuvant\\:\\ 0\\.05885466151934709\ \(0\)\
\-\ resistant\\:\\ 0\\.0584926993694011\ \(0\)\
\-\ lobe\\:\\ 0\\.058459431636126845\ \(0\)\
\-\ therapy\\:\\ 0\\.058122624031218886\ \(0\)\
\-\ urethra\\:\\ 0\\.05781029802573591\ \(0\)\
\-\ favorable\\:\\ 0\\.05781029802573591\ \(0\)\
\-\ profile\\:\\ 0\\.05781029802573591\ \(0\)\
\-\ are\\:\\ 0\\.057578075350764424\ \(0\)\
\-\ opposed\\:\\ 0\\.05748783189375823\ \(0\)\
\-\ mainly\\:\\ 0\\.0568760830464065\ \(0\)\
\-\ layering\\:\\ 0\\.05658534088878192\ \(0\)\
\-\ careful\\:\\ 0\\.0560309828008368\ \(0\)\
\-\ sufficient\\:\\ 0\\.0557662813120706\ \(0\)\
\-\ acetabulum\\:\\ 0\\.05550925342081764\ \(0\)\
\-\ metastatic\\:\\ 0\\.055480858874913073\ \(0\)\
\-\ congestive\\:\\ 0\\.05525946672341191\ \(0\)\
\-\ urinalysis\\:\\ 0\\.0547800612489223\ \(0\)\
\-\ transitional\\:\\ 0\\.054549740731394625\ \(0\)\
\-\ bilateral\\:\\ 0\\.054366783066871344\ \(0\)\
\-\ cancers\\:\\ 0\\.054325251744082495\ \(0\)\
\-\ already\\:\\ 0\\.05368399590985594\ \(0\)\
\-\ obstructing\\:\\ 0\\.05348015149851279\ \(0\)\
\-\ clot\\:\\ 0\\.0527086354210879\ \(0\)\
\-\ posterior\\:\\ 0\\.052310387324240294\ \(0\)\
\-\ were\\:\\ 0\\.05214473677393144\ \(0\)\
\-\ it\\:\\ 0\\.051782072135866115\ \(0\)\
\-\ lower\\:\\ 0\\.051692553103035874\ \(0\)\
\-\ 82\\:\\ 0\\.0515015730255722\ \(0\)\
\-\ produced\\:\\ 0\\.0515015730255722\ \(0\)\
\-\ right\\:\\ 0\\.050307779457273154\ \(0\)\
\-\ up\\:\\ 0\\.05003973288538622\ \(0\)\
\-\ infiltration\\:\\ 0\\.0498849567025776\ \(0\)\
\-\ contrast\\:\\ 0\\.049151276762112374\ \(0\)\
\-\ concerning\\:\\ 0\\.04851812707698874\ \(0\)\
\-\ here\\:\\ 0\\.0481792256458233\ \(0\)\
\-\ remaining\\:\\ 0\\.04806907713154153\ \(0\)\
\-\ half\\:\\ 0\\.04764167674087082\ \(0\)\
\-\ clearly\\:\\ 0\\.04764167674087082\ \(0\)\
\-\ painless\\:\\ 0\\.046844119994587534\ \(0\)\
\-\ within\\:\\ 0\\.04659089049838786\ \(0\)\
\-\ need\\:\\ 0\\.046562609322828706\ \(0\)\
\-\ frequent\\:\\ 0\\.04637978137397498\ \(0\)\
\-\ normally\\:\\ 0\\.04611241916759748\ \(0\)\
\-\ uncommon\\:\\ 0\\.04576803252662325\ \(0\)\
\-\ contour\\:\\ 0\\.04551824582921752\ \(0\)\
\-\ six\\:\\ 0\\.045436523210411285\ \(0\)\
\-\ included\\:\\ 0\\.0437389306043184\ \(0\)\
\-\ having\\:\\ 0\\.04360559213113841\ \(0\)\
\-\ those\\:\\ 0\\.04328076308339107\ \(0\)\
\-\ distended\\:\\ 0\\.04321720122429925\ \(0\)\
\-\ material\\:\\ 0\\.04260545237694752\ \(0\)\
\-\ recurrence\\:\\ 0\\.041760352131377826\ \(0\)\
\-\ femur\\:\\ 0\\.04149565064261162\ \(0\)\
\-\ normal\\:\\ 0\\.041302696077447486\ \(0\)\
\-\ screening\\:\\ 0\\.041087907937970826\ \(0\)\
\-\ be\\:\\ 0\\.04103631586208125\ \(0\)\
\-\ metastases\\:\\ 0\\.04089085890928737\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.04089085890928737\ \(0\)\
\-\ as\\:\\ 0\\.04063931266326611\ \(0\)\
\-\ 45\\:\\ 0\\.040556221407693466\ \(0\)\
\-\ rule\\:\\ 0\\.04014373580838322\ \(0\)\
\-\ limits\\:\\ 0\\.03996639306933829\ \(0\)\
\-\ not\\:\\ 0\\.03993531643529025\ \(0\)\
\-\ visualized\\:\\ 0\\.03949623351995459\ \(0\)\
\-\ considered\\:\\ 0\\.03941336524039696\ \(0\)\
\-\ line\\:\\ 0\\.03941336524039696\ \(0\)\
\-\ includes\\:\\ 0\\.03933126427073948\ \(0\)\
\-\ evaluate\\:\\ 0\\.03933126427073948\ \(0\)\
\-\ vessels\\:\\ 0\\.03924991653160238\ \(0\)\
\-\ shown\\:\\ 0\\.03920952082905381\ \(0\)\
\-\ vs\\:\\ 0\\.03858703080367974\ \(0\)\
\-\ failure\\:\\ 0\\.03840113633521284\ \(0\)\
\-\ used\\:\\ 0\\.037865751922245505\ \(0\)\
\-\ metastasis\\:\\ 0\\.03707117512604005\ \(0\)\
\-\ did\\:\\ 0\\.036283839523681825\ \(0\)\
\-\ required\\:\\ 0\\.036111662436617044\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.03591492571412996\ \(0\)\
\-\ wbc\\:\\ 0\\.03574970028667104\ \(0\)\
\-\ biopsy\\:\\ 0\\.035454558803045454\ \(0\)\
\-\ heart\\:\\ 0\\.035168925744596014\ \(0\)\
\-\ new\\:\\ 0\\.03499183600774455\ \(0\)\
\-\ enlarged\\:\\ 0\\.034480847805747734\ \(0\)\
\-\ thickening\\:\\ 0\\.034410195309434274\ \(0\)\
\-\ first\\:\\ 0\\.03413308396367645\ \(0\)\
\-\ cases\\:\\ 0\\.03402012904285973\ \(0\)\
\-\ initial\\:\\ 0\\.03393078983494467\ \(0\)\
\-\ out\\:\\ 0\\.033246742521092255\ \(0\)\
\-\ patient\\:\\ 0\\.032902067619712795\ \(0\)\
\-\ no\\:\\ 0\\.032895878932598425\ \(0\)\
\-\ aspect\\:\\ 0\\.032630880084535165\ \(0\)\
\-\ resection\\:\\ 0\\.03242223889656806\ \(0\)\
\-\ show\\:\\ 0\\.032109150704516\ \(0\)\
\-\ usually\\:\\ 0\\.0318417884981385\ \(0\)\
\-\ yo\\:\\ 0\\.031599320696214864\ \(0\)\
\-\ renal\\:\\ 0\\.03149740185716427\ \(0\)\
\-\ evaluation\\:\\ 0\\.03084633214105802\ \(0\)\
\-\ when\\:\\ 0\\.030553059131019186\ \(0\)\
\-\ abnormal\\:\\ 0\\.03038760012282837\ \(0\)\
\-\ likely\\:\\ 0\\.0302251721751439\ \(0\)\
\-\ include\\:\\ 0\\.030094454701502085\ \(0\)\
\-\ months\\:\\ 0\\.029441471347453122\ \(0\)\
\-\ due\\:\\ 0\\.02907415320738769\ \(0\)\
\-\ cell\\:\\ 0\\.028933912677782524\ \(0\)\
\-\ evidence\\:\\ 0\\.028709107474947346\ \(0\)\
\-\ these\\:\\ 0\\.028562342611866673\ \(0\)\
\-\ physical\\:\\ 0\\.027425468707040275\ \(0\)\
\-\ consistent\\:\\ 0\\.027425468707040275\ \(0\)\
\-\ tumor\\:\\ 0\\.026456112173838368\ \(0\)\
\-\ exam\\:\\ 0\\.025461840951748044\ \(0\)\
\-\ may\\:\\ 0\\.025453294597955672\ \(0\)\
\-\ large\\:\\ 0\\.02534293516676543\ \(0\)\
\-\ had\\:\\ 0\\.025200660945517248\ \(0\)\
\-\ which\\:\\ 0\\.02299908802267961\ \(0\)\
\-\ by\\:\\ 0\\.021479069617212066\ \(0\)\
\-\ history\\:\\ 0\\.019324369452679308\ \(0\)\
\-\ ct\\:\\ 0\\.019256162644251475\ \(0\)\
\-\ was\\:\\ 0\\.017627522524627702\ \(0\)\
\-\ or\\:\\ 0\\.017595773307352694\ \(0\)\
\-\ left\\:\\ 0\\.01725383520375116\ \(0\)\
\-\ on\\:\\ 0\\.015275934390742353\ \(0\)\
\-\ in\\:\\ 0\\.01258258520819788\ \(0\)\
